Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY 4.0Cureus

Oral Ketamine-Assisted Psychotherapy Leading to Prolonged Remission in Recurrent Dissociative Neurological Symptom Disorder With Mutism: A Case Report

  1. 1Psychiatry, All India Institute of Medical Sciences, Bibinagar, Hyderabad, IND

Abstract

Dissociative neurological symptom disorder (DNSD), termed functional neurological symptom disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), presents with neurological symptoms not explained by structural disease. The first line treatment of DNSD is psychotherapy, but when the conflict maintaining the symptoms cannot be put into words, psychotherapy often stalls. This report describes a 56-year-old woman with a four-year history of episodic loss of consciousness and progressive speech loss, with normal neurological investigations. Escitalopram, intravenous ketamine infusions given without psychotherapy, and venlafaxine produced no meaningful benefit. A 30-day inpatient program of psychotherapy, family therapy, and speech therapy restored her speech, but she relapsed into complete mutism four months after discharge, and no stressor could be identified. A lorazepam-assisted interview produced sedation without speech. She then received six alternate-day sessions of oral ketamine-assisted psychotherapy, titrated from 50 mg to 150 mg, within a psychodynamically informed frame; while venlafaxine 225 mg/day was continued and family therapy was delivered alongside. She spoke a few words in the third session (100 mg) and conversed spontaneously in the fourth (150 mg), describing a conflict between a rigid moral self-image of never being greedy and unspoken distress over a family property dispute. Speech has been sustained for more than one year, and all psychotropic medication has since been withdrawn. The report proposes that, this single case is hypothesis-generating. It suggests that ketamine may be a useful and a better abreactive agent in selected patients with treatment-resistant DNSD, and that the therapeutic frame is also essential for the improvement to happen, and further controlled comparison with benzodiazepine-assisted interviews is warranted in the future.

Related

  1. Multiple Neurological Complications and Multidrug-Resistant Bacterial Infections During Prolonged Intensive Care for Undocumented Meningoencephalitis in Côte d'Ivoire: A Case Report
    Setondji Emmanuel Raymond Ahouangansi, Loes Koffi, Zolé Cédric Doh +8
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Prolonged treatment-free remission after venetoclax in combination with a hypomethylating agent in acute myeloid leukemia with inv(16).
    Morgan L Shannon, Jared Wallace, Amy Kuo +1
    Annals of hematologyPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMCPMC
  3. Case Report: Prolonged survival with short-course triplet induction and dual maintenance in recurrent/metastatic cervical cancer
    Yiqing Duan, Dan Liu, Qian Huang +3
    Frontiers in OncologyPeer-reviewedCC BY 4.0Full textObstetrics, gynaecology & paediatricsCrossrefEurope PMCPMCEurope PMC
  4. Case Report: Four-year durable remission, cerebral oligoprogression, and femoral head necrosis following severe recurrent immune checkpoint inhibitor-related pneumonitis in a patient with stage IV lung adenocarcinoma
    Yanjun Xue, Aizhen Xu, Xin Tong +2
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMCEurope PMCPMC
  5. Prolonged fever as a harbinger: the diagnostic and therapeutic challenge of recurrent complicated urinary tract infection following congenital dermal sinus excision in an infant: a case report
    Lihui Liao, Wentao Peng
    Frontiers in PediatricsPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
BibTeX
@article{bakam2026oral,
  title = {{Oral Ketamine-Assisted Psychotherapy Leading to Prolonged Remission in Recurrent Dissociative Neurological Symptom Disorder With Mutism: A Case Report}},
  author = {Anirudh Bakam},
  journal = {Cureus},
  year = {2026},
  month = oct,
  doi = {10.7759/cureus.117827},
  url = {https://doi.org/10.7759/cureus.117827},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Oral Ketamine-Assisted Psychotherapy Leading to Prolonged Remission in Recurrent Dissociative Neurological Symptom Disorder With Mutism: A Case Report
AU  - Anirudh Bakam
PY  - 2026
DA  - 2026/10/12
JO  - Cureus
DO  - 10.7759/cureus.117827
UR  - https://doi.org/10.7759/cureus.117827
AB  - Dissociative neurological symptom disorder (DNSD), termed functional neurological symptom disorder in the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR), presents with neurological symptoms not explained by structural disease. The first line treatment of DNSD is psychotherapy, but when the conflict maintaining the symptoms cannot be put into words, psychotherapy often stalls. This report describes a 56-year-old woman with a four-year history of episodic loss of consciousness and progressive speech loss, with normal neurological investigations. Escitalopram, intravenous ketamine infusions given without psychotherapy, and venlafaxine produced no meaningful benefit. A 30-day inpatient program of psychotherapy, family therapy, and speech therapy restored her speech, but she relapsed into complete mutism four months after discharge, and no stressor could be identified. A lorazepam-assisted interview produced sedation without speech. She then received six alternate-day sessions of oral ketamine-assisted psychotherapy, titrated from 50 mg to 150 mg, within a psychodynamically informed frame; while venlafaxine 225 mg/day was continued and family therapy was delivered alongside. She spoke a few words in the third session (100 mg) and conversed spontaneously in the fourth (150 mg), describing a conflict between a rigid moral self-image of never being greedy and unspoken distress over a family property dispute. Speech has been sustained for more than one year, and all psychotropic medication has since been withdrawn. The report proposes that, this single case is hypothesis-generating. It suggests that ketamine may be a useful and a better abreactive agent in selected patients with treatment-resistant DNSD, and that the therapeutic frame is also essential for the improvement to happen, and further controlled comparison with benzodiazepine-assisted interviews is warranted in the future.
SN  - 2168-8184
ER  -